Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Controlled Multi-centre Trial to Evaluate the Efficacy of the R21/Matrix-M Vaccine in African Children Against Clinical Malaria

NCT04704830 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT04704830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04704830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Controlled Multi-centre Trial to Evaluate the Efficacy of the R21/Matrix-M Vaccine in African Children Against Clinical Malaria
Lead sponsor
University of Oxford
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 29, 2021
Completion date
April 30, 2028
Enrollment
4,800 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria